Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy of Camostat Mesilate for Treatment of COVID-19 in Outpatients

NCT04583592 is registered in ClinicalTrials.gov with Sagent Pharmaceuticals Inc. as lead sponsor.

NCT NCT04583592
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04583592 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy of Camostat Mesilate for Treatment of COVID-19 in Outpatients
Lead sponsor
Sagent Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 9, 2020
Completion date
March 31, 2021
Enrollment
295 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19